𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Risk of second cancer after lymphohematopoietic neoplasm

✍ Scribed by Jill S. Royle; Peter Baade; David Joske; Lin Fritschi


Publisher
John Wiley and Sons
Year
2010
Tongue
French
Weight
145 KB
Volume
129
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

People living with lymphohematopoietic neoplasms (LHNs) are known to have increased risks of second cancer; however, the incidence of second cancers after LHNs has not been studied extensively in Australia. The Australian Cancer Database was used to analyze site‐specific risk of second primary cancer after LHNs in 127,707 patients diagnosed between 1983 and 2005. Standardized incidence ratios (SIRs) were calculated using population rates. Overall, patients with an LHN had nearly twice the risk of developing a second cancer compared to the Australian population. Among 40,321 patients with non‐Hodgkin's lymphoma (NHL), there was over a fourfold significant increase in melanoma, Kaposi sarcoma, cancer of the lip, connective tissue and peripheral nerves, eye, thyroid, Hodgkin's disease (HD) and myeloid leukemia. Among 6,396 patients with HD, there was over a fourfold significant increase in melanoma, Kaposi sarcoma, cancer of the lip, oral cavity and pharynx, female breast, uterine cervix, testis, thyroid, NHL and myeloid leukemia. Among the 33,025 patients with lymphoid and myeloid leukemia, significant excess were seen for cancers of the lip, eye, connective tissue and peripheral nerves, NHL and HD. Among the 13,856 patients with plasma cell tumors, there was over fourfold significant increase for melanoma, cancer of the connective tissue and peripheral nerves and myeloid leukemia. Our findings provide evidence of an increased risk of cancer, particularly ultraviolet radiation‐ and immunosuppression‐related cancers, after an LHN in Australia.


📜 SIMILAR VOLUMES


Second neoplasms after oesophageal cance
✍ Fabio Levi; Lalao Randimbison; Manuela Maspoli; Van-Cong Te; Carlo La Vecchia 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 108 KB

## Abstract The authors considered the incidence of second neoplasms among 1,672 oesophageal cancers diagnosed between 1974 and 2004 in the Cancer Registries of the Swiss Cantons of Vaud and Neuchâtel, and followed‐up to 2004. A total of 141 second neoplasms were observed versus 38.5 expected, corr

Risk of second cancer after chronic lymp
✍ Claudia Schöllkopf; Ditte Rosendahl; Klaus Rostgaard; Christian Pipper; Henrik H 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 89 KB

## Abstract Smoking is not considered a risk factor for chronic lymphocytic leukemia (CLL) yet increased lung cancer risk has been reported for these patients. Little data exist on the temporal variation in lung cancer risk after CLL, or its histological composition. We investigated the occurrence

Long-term risk of second malignant neopl
✍ Carole Rubino; Elisabeth Adjadj; Sylvie Guérin; Catherine Guibout; Akhtar Shamsa 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 90 KB

## Abstract The aim of our study was to quantify the risk of second malignant neoplasms (SMNs) among long‐term survivors of neuroblastoma and to study the influence of treatment on this risk. We studied data from 544 5‐year survival patients diagnosed with neuroblastoma before age 16 years at 8 Fre

Risk of second malignant neoplasms among
✍ Ola Landgren; Ruth M. Pfeiffer; Laveta Stewart; Gloria Gridley; Lene Mellemkjaer 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 73 KB 👁 2 views

## Abstract Radiotherapy and chemotherapy are known risk factors for second cancers after lymphoma. The role of genetic influences, however, remains largely unknown. We assessed risk of second cancers associated with family history of any cancer in 41,181 patients with Hodgkin lymphoma (HL) (__n__

Pattern of second primary neoplasms foll
✍ Parikh, Bhavna; Advani, Suresh 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB 👁 2 views

Background: Second primary neoplasms (SPN) have been seen with diseases such as breast cancer and Hodgkin's disease. Therapeutic agents used for their treatment have been found responsible for the development of SPN in some cases. In addition, genetic factors are known to contribute to their develop